Two phase III clinical trials of Ampyra showed 35 and 43 percent of patients experienced, on average, a consistent improvement in their walking speed, increasing it by about 25 percent.Drugs work differently for different people, but hopefully this new oral medication will help many in allowing more to be ambulatory and give them back their independence.
According to the National Multiple Sclerosis Society, even a modest improvement in walking ability could mean that thousands of people could benefit from the drug.
Dr. John Richert, executive vice president of Research & Clinical Programs at the National Multiple Sclerosis Society, says the drug can be used by most people with MS. However, the drug is not for people with a history of seizures or people who have moderate to severe kidney disease.
Richert says approval means patients can now skip the compounding pharmacy and get a consistent, exact dosage in a guaranteed time-released formula, which would lower the risk of getting a toxic dose instead of a therapeutic dose.
Friday, January 22, 2010
New MS Drug
So many people with Multiple Sclerosis have to deal with a lack of movement and daily injections. The FDA has now approved a new oral drug for MS that will hopefully be of help for many. According to CNN News: